Related Content
- Big Molecule WatchOctober 18, 2024
Teva’s Denosumab Biosimilar Candidate is Accepted for Review by FDA and EMA
- Big Molecule WatchOctober 16, 2024
Teva and mAbxience Add Additional Oncology Biosimilar Candidate, Expanding Strategic Partnership
- Big Molecule WatchOctober 14, 2024
Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab
- Big Molecule WatchOctober 7, 2024
PTAB Institutes Eight More IPRs Filed by Merck on Johns Hopkins Pembrolizumab Patents
- Big Molecule WatchOctober 5, 2024
Fresenius and Formycon Receive EC and FDA Approval of Ustekinumab Biosimilar
- Big Molecule WatchOctober 4, 2024
Aflibercept Biosimilar Updates in Europe
- Big Molecule WatchOctober 3, 2024
Express Scripts Sues FTC Over Report on Pharmacy Benefit Management Industry
- Big Molecule WatchSeptember 27, 2024
Recent Biosimilar Approvals By the FDA
- Awards and RankingsSeptember 9, 2024
Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year